化痰解毒方联合分子靶向治疗晚期非小细胞肺癌临床观察
发布时间：2019-06-26 08:35
【摘要】：目的:观察化痰解毒方联合分子靶向药物治疗晚期非小细胞肺癌患者的近期疗效、生活质量变化及毒副反应情况等,以评价中医药在晚期非小细胞肺癌治疗中的作用与优势。方法:选取2013年1月至2014年12月新疆维吾尔自治区中医医院肿瘤科病房及门诊经治的IIIb期或IV期非小细胞肺癌患者63例,随机分配至治疗组32例,对照组31例,治疗组采用化痰解毒方联合分子靶向药物(厄洛替尼、吉非替尼或者埃克替尼其中之一),对照组采用单纯靶向治疗(厄洛替尼、吉非替尼或者埃克替尼其中之一),治疗1月评估疗效。结果:①治疗组与对照组的有效率为18.75%和12.90%(P=0.525),无统计学意义;治疗组与对照组的疾病控制率为75.00%和77.42%(P=0.946),无统计学意义。②治疗组与对照组治疗前后患者的中医证候积分,经统计学检验,P0.05,有统计学差异;治疗组与对照组治疗前后患者的KPS评分,经统计学检验,P0.05,有统计学差异。③治疗组在皮疹、消化道反应、转氨酶升高等毒副反应及安全性方面较对照组发生率小。结论:化痰解毒方联合靶向治疗可有效缓解靶向治疗毒副反应,改善患者临床症状,提高患者生活质量,起到减毒增效的作用。
[Abstract]:Objective: to observe the short-term efficacy, quality of life (QOL) and side effects of Huatan Jiedu recipe combined with molecular targeted drugs in the treatment of advanced non-small cell lung cancer (NSCLC), so as to evaluate the role and advantages of traditional Chinese medicine (TCM) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: from January 2013 to December 2014, 63 patients with IIIb or IV stage non-small cell lung cancer in oncology department and outpatient department of Xinjiang Uygur Autonomous region Hospital of traditional Chinese Medicine were randomly assigned to the treatment group (32 cases) and the control group (31 cases). The treatment group was treated with Huatan jiedu recipe combined with molecular targeting drugs (alotinib, gefitinib or one of the ectene), while the control group was treated with only targeted therapy (erlotinib. Gefitinib or one of the actinis), evaluated the efficacy of one month of treatment. Results: 1the effective rates of the treatment group and the control group were 18.75% and 12.90% (P 鈮，
本文编号：2506063
[Abstract]:Objective: to observe the short-term efficacy, quality of life (QOL) and side effects of Huatan Jiedu recipe combined with molecular targeted drugs in the treatment of advanced non-small cell lung cancer (NSCLC), so as to evaluate the role and advantages of traditional Chinese medicine (TCM) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: from January 2013 to December 2014, 63 patients with IIIb or IV stage non-small cell lung cancer in oncology department and outpatient department of Xinjiang Uygur Autonomous region Hospital of traditional Chinese Medicine were randomly assigned to the treatment group (32 cases) and the control group (31 cases). The treatment group was treated with Huatan jiedu recipe combined with molecular targeting drugs (alotinib, gefitinib or one of the ectene), while the control group was treated with only targeted therapy (erlotinib. Gefitinib or one of the actinis), evaluated the efficacy of one month of treatment. Results: 1the effective rates of the treatment group and the control group were 18.75% and 12.90% (P 鈮，
本文编号：2506063
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2506063.html
